Payment overview · 2025
General Payments
$156.82
9 reported records · 6 companies
Healthcare provider profile · identity verified
Tolga Icli, MD
Allopathic & Osteopathic Physicians|Family Medicine · AUSTINTOWN, OH · NPI 1114182979
Verified facts
What the public records show
CMS Open Payments records show Tolga Icli, MD received $156.82 in general payments during 2025 across 9 reported records.
Lilly USA, LLC accounted for 21.5% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 12 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Mounjaro, Ozempic.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Synthroid by this doctor in 2024.
Amgen Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PROLIA as an associated drug or biological on 20867 records involving 11744 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Prolia by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 76 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 37 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 77 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 42 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 503 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $33.67 | 21.5% | 2 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $33.59 | 21.4% | 2 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $32.30 | 20.6% | 2 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $22.88 | 14.6% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $17.22 | 11.0% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $17.16 | 10.9% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $156.82 | 9 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $33.67 | 2 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $33.59 | 2 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $33.59 | 2 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $22.88 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $22.88 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $19.85 | 1 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $17.73 | 1 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $17.22 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $17.22 | 1 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $17.16 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $17.16 | 1 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $14.57 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 503 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 37 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 42 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| Amgen Inc. Exact reporting entity; no affiliate inference |
2025 | PROLIA open payments reported associated product |
CMS Open Payments — General Payments 20867 supporting records · 11744 recipient NPIs · example record 1226874448 |
Prolia · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
76 | 16 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
37 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
77 | 11 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
42 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
503 | 84 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 564 | 102 |
| Eliquis | Apixaban | 503 | 84 |
| Atorvastatin Calcium | Atorvastatin Calcium | 450 | 98 |
| Amlodipine Besylate | Amlodipine Besylate | 312 | 73 |
| Pantoprazole Sodium | Pantoprazole Sodium | 289 | 69 |
| Metoprolol Succinate | Metoprolol Succinate | 281 | 70 |
| Lisinopril | Lisinopril | 272 | 68 |
| Potassium Chloride | Potassium Chloride | 261 | 53 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 250 | 62 |
| Omeprazole | Omeprazole | 240 | 54 |
| Gabapentin | Gabapentin | 226 | 49 |
| Furosemide | Furosemide | 203 | 45 |
| Pravastatin Sodium | Pravastatin Sodium | 185 | 36 |
| Metoprolol Tartrate | Metoprolol Tartrate | 166 | 44 |
| Famotidine | Famotidine | 163 | 30 |
| Metformin Hcl | Metformin Hcl | 160 | 37 |
| Allopurinol | Allopurinol | 138 | 25 |
| Memantine Hcl | Memantine Hcl | 138 | 24 |
| Tamsulosin Hcl | Tamsulosin Hcl | 136 | 28 |
| Clopidogrel | Clopidogrel Bisulfate | 135 | 20 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 120 | 31 |
| Losartan Potassium | Losartan Potassium | 114 | 22 |
| Mirtazapine | Mirtazapine | 114 | 27 |
| Donepezil Hcl | Donepezil Hcl | 111 | 20 |
| Duloxetine Hcl | Duloxetine Hcl | 110 | 30 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 108 | 20 |
| Alendronate Sodium | Alendronate Sodium | 105 | 22 |
| Meloxicam | Meloxicam | 104 | 23 |
| Hydrochlorothiazide | Hydrochlorothiazide | 103 | 19 |
| Escitalopram Oxalate | Escitalopram Oxalate | 101 | 18 |
| Bumetanide | Bumetanide | 92 | 28 |
| Sertraline Hcl | Sertraline Hcl | 89 | 19 |
| Montelukast Sodium | Montelukast Sodium | 87 | 15 |
| Hydralazine Hcl | Hydralazine Hcl | 86 | 18 |
| Carvedilol | Carvedilol | 85 | 18 |
| Gemfibrozil | Gemfibrozil | 79 | 15 |
| Trulicity | Dulaglutide | 77 | 11 |
| Jardiance | Empagliflozin | 76 | 16 |
| Simvastatin | Simvastatin | 76 | 16 |
| Baclofen | Baclofen | 73 | 14 |
| Folic Acid | Folic Acid | 70 | 20 |
| Pregabalin | Pregabalin | 67 | 12 |
| Meclizine Hcl | Meclizine Hcl | 65 | 26 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 65 | 18 |
| Quetiapine Fumarate | Quetiapine Fumarate | 64 | suppressed |
| Januvia | Sitagliptin Phosphate | 63 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 61 | 22 |
| Primidone | Primidone | 60 | suppressed |
| Glipizide | Glipizide | 57 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 57 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 56 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 56 | 14 |
| Levetiracetam | Levetiracetam | 55 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 54 | 14 |
| Torsemide | Torsemide | 54 | 12 |
| Ondansetron Hcl | Ondansetron Hcl | 53 | 39 |
| Prednisone | Prednisone | 51 | 20 |
| Ipratropium Bromide | Ipratropium Bromide | 49 | 17 |
| Rivastigmine | Rivastigmine | 49 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 47 | 13 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 47 | 20 |
| Spironolactone | Spironolactone | 47 | 14 |
| Midodrine Hcl | Midodrine Hcl | 46 | 11 |
| Trazodone Hcl | Trazodone Hcl | 46 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 44 | suppressed |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 44 | suppressed |
| Verapamil Er | Verapamil Hcl | 43 | suppressed |
| Ezetimibe | Ezetimibe | 42 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 42 | suppressed |
| Ozempic | Semaglutide | 42 | suppressed |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 41 | 28 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 41 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 41 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 41 | 11 |
| Buspirone Hcl | Buspirone Hcl | 40 | 12 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 39 | 17 |
| Sucralfate | Sucralfate | 39 | suppressed |
| Digoxin | Digoxin | 38 | suppressed |
| Lactulose | Lactulose | 38 | suppressed |
| Mounjaro | Tirzepatide | 37 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 37 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 37 | suppressed |
| Latanoprost | Latanoprost | 35 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 32 | 16 |
| Bupropion Xl | Bupropion Hcl | 32 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 32 | 27 |
| Diltiazem 24hr Er | Diltiazem Hcl | 32 | suppressed |
| Synjardy | Empagliflozin/Metformin Hcl | 32 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 32 | 11 |
| Lovastatin | Lovastatin | 31 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 31 | suppressed |
| Clozapine | Clozapine | 30 | suppressed |
| Fenofibrate | Fenofibrate | 30 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 30 | suppressed |
| Vascepa | Icosapent Ethyl | 30 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 29 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 28 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 27 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 26 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 26 | suppressed |
| Glimepiride | Glimepiride | 26 | suppressed |
| Ibuprofen | Ibuprofen | 26 | 11 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 26 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 25 | suppressed |
| Finasteride | Finasteride | 25 | suppressed |
| Rexulti | Brexpiprazole | 25 | suppressed |
| Topiramate | Topiramate | 25 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 24 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 24 | suppressed |
| Propafenone Hcl | Propafenone Hcl | 24 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 24 | suppressed |
| Azithromycin | Azithromycin | 23 | 21 |
| Rivastigmine | Rivastigmine Tartrate | 23 | suppressed |
| Cephalexin | Cephalexin | 22 | 16 |
| Clonazepam | Clonazepam | 22 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 22 | suppressed |
| Lorazepam | Lorazepam | 22 | 14 |
| Methylprednisolone | Methylprednisolone | 22 | 20 |
| Myrbetriq | Mirabegron | 22 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 22 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 20 | suppressed |
| Glipizide Er | Glipizide | 20 | suppressed |
| Naproxen | Naproxen | 20 | 13 |
| Breo Ellipta | Fluticasone/Vilanterol | 19 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 19 | 16 |
| Doxycycline Hyclate | Doxycycline Hyclate | 19 | 18 |
| Fluvoxamine Maleate | Fluvoxamine Maleate | 19 | suppressed |
| Nifedipine Er | Nifedipine | 19 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 19 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 18 | suppressed |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 18 | suppressed |
| Ramipril | Ramipril | 18 | suppressed |
| Calcitriol | Calcitriol | 17 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 17 | suppressed |
| Nystatin | Nystatin | 17 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 17 | suppressed |
| Albuterol Sulfate | Albuterol Sulfate | 16 | suppressed |
| Buprenorphine-Naloxone | Buprenorphine Hcl/Naloxone Hcl | 16 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 16 | suppressed |
| Fluconazole | Fluconazole | 16 | 12 |
| Levemir Flexpen | Insulin Detemir | 16 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 16 | suppressed |
| Atenolol | Atenolol | 15 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 15 | suppressed |
| Budesonide | Budesonide | 15 | suppressed |
| Combigan | Brimonidine Tartrate/Timolol | 15 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 15 | suppressed |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 15 | suppressed |
| Lamotrigine | Lamotrigine | 15 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 15 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 15 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 15 | suppressed |
| Repatha Sureclick | Evolocumab | 15 | suppressed |
| Cefdinir | Cefdinir | 14 | 14 |
| Enalapril Maleate | Enalapril Maleate | 14 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 14 | suppressed |
| Icosapent Ethyl | Icosapent Ethyl | 14 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 14 | suppressed |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 14 | suppressed |
| Loperamide | Loperamide Hcl | 14 | 11 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 14 | suppressed |
| Carbamazepine | Carbamazepine | 13 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 13 | suppressed |
| Methenamine Hippurate | Methenamine Hippurate | 13 | suppressed |
| Permethrin | Permethrin | 13 | 11 |
| Propranolol Hcl | Propranolol Hcl | 13 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 13 | suppressed |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 12 | suppressed |
| Ammonium Lactate | Ammonium Lactate | 12 | suppressed |
| Amoxicillin | Amoxicillin | 12 | suppressed |
| Autoshield Duo Pen Needle | Pen Needle,dual Safety,diabetc | 12 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 12 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 12 | suppressed |
| Phenytoin | Phenytoin | 12 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 12 | suppressed |
| Prolia | Denosumab | 12 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 12 | suppressed |
| Synthroid | Levothyroxine Sodium | 12 | suppressed |
| Cholestyramine | Cholestyramine (With Sugar) | 11 | suppressed |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 11 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 11 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 11 | suppressed |
| Ramelteon | Ramelteon | 11 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $156.82 · 9 records | Lilly USA, LLC | AIRSUPRA, BREZTRI, ELIQUIS, MOUNJARO, NURTEC ODT, OTEZLA, Ozempic, QULIPTA, REPATHA, Rybelsus, UBRELVY, ZEPBOUND | 7 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error